{"title":"The Association Between the Hemoglobin Glycation Index and Cardiometabolic Diseases: A Mini-Review","authors":"Qing-Yun Wu, Li-Rong Mo, Jing Nan, Wan-Zhong Huang, Qiang Wu, Qiang Su","doi":"10.1111/jch.70092","DOIUrl":null,"url":null,"abstract":"<p>The hemoglobin glycation index (HGI) has emerged as a pivotal biomarker for evaluating long-term glycemic control, offering a more comprehensive assessment compared with conventional glycated hemoglobin (HbA1c) measurements. Elevated HGI levels are significantly correlated with the incidence of cardiometabolic diseases (CMDs). This review synthesizes current evidence on the clinical utility of the HGI across coronary artery disease (CAD), hypertension, heart failure (HF), diabetes mellitus (DM), serum uric acid (SUA) levels, and nonalcoholic fatty liver disease (NAFLD), thereby providing clinicians with an enhanced framework for precise disease stratification, therapeutic optimization, and prognostic prediction.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"27 7","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.70092","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Hypertension","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jch.70092","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
The hemoglobin glycation index (HGI) has emerged as a pivotal biomarker for evaluating long-term glycemic control, offering a more comprehensive assessment compared with conventional glycated hemoglobin (HbA1c) measurements. Elevated HGI levels are significantly correlated with the incidence of cardiometabolic diseases (CMDs). This review synthesizes current evidence on the clinical utility of the HGI across coronary artery disease (CAD), hypertension, heart failure (HF), diabetes mellitus (DM), serum uric acid (SUA) levels, and nonalcoholic fatty liver disease (NAFLD), thereby providing clinicians with an enhanced framework for precise disease stratification, therapeutic optimization, and prognostic prediction.
期刊介绍:
The Journal of Clinical Hypertension is a peer-reviewed, monthly publication that serves internists, cardiologists, nephrologists, endocrinologists, hypertension specialists, primary care practitioners, pharmacists and all professionals interested in hypertension by providing objective, up-to-date information and practical recommendations on the full range of clinical aspects of hypertension. Commentaries and columns by experts in the field provide further insights into our original research articles as well as on major articles published elsewhere. Major guidelines for the management of hypertension are also an important feature of the Journal. Through its partnership with the World Hypertension League, JCH will include a new focus on hypertension and public health, including major policy issues, that features research and reviews related to disease characteristics and management at the population level.